XEN D0101

Drug Profile

XEN D0101

Alternative Names: XEN-D0101

Latest Information Update: 25 Mar 2016

Price : $50

At a glance

  • Originator Galapagos NV
  • Developer Xention
  • Class Antiarrhythmics
  • Mechanism of Action Kv1.5 potassium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atrial fibrillation

Most Recent Events

  • 25 Mar 2016 Discontinued - Phase-I for Atrial fibrillation in Europe (unspecified route)
  • 09 Sep 2011 Phase I development is ongoing in Europe
  • 09 Oct 2006 Phase-I clinical trials in Atrial fibrillation in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top